Browse > Article
http://dx.doi.org/10.15429/jkomor.2021.21.2.95

Analysis of Safety of Mahuang in Studies for Treatment of Obesity  

Cho, Minjin (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University)
Kim, Sungha (Korean Medicine Science Research Division, Korea Institute of Oriental Medicine)
Kim, Hojun (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University)
Song, Mi Young (The Reset Korean Medical Clinic)
Publication Information
Journal of Korean Medicine for Obesity Research / v.21, no.2, 2021 , pp. 95-104 More about this Journal
Abstract
Objectives: The purpose of this study is to analyze the adverse events and safety of Mahuang used as anti-obesity treatment in Korean medicine. Methods: PubMed, EMBASE, Cochrane, KoreaMed, Oriental Medicine Advanced Searching Integrated System (OASIS) and SCIENCE-ON were used as searching for randomized controlled trials investigating the safety of Mahuang for treating obesity from January, 2000 to July, 2021. Results: Total 6 studies were included for analyzing. In most studies, heart rate was higher in experimental group than in placebo group with statistically significant difference. Both systolic and diastolic blood pressure had no significant differences between both groups, but systolic blood pressure got lower in experimental group. Most adverse events reported in experimental group were dry mouth, constipation, diarrhea, palpitation and insomnia, but serious adverse events were not reported. Conclusions: This study provides the evidence about the safety of Mahuang for treating obesity. However, increase of heart rate and minor adverse events could be occurred. Further study is needed to confirm the safety of Mahuang.
Keywords
Systematic review; Meta-analysis; Ephedra sinica; Safety;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Nam GE, Kim YH, Han KD, Jung JH, Rhee EJ, Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr. 2021 ; 30(2) : 141-2.   DOI
2 Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Current Obesity Reports. 2018 ; 7(2) : 147-61.   DOI
3 KIOM. Obesity Korean medicine clinical practice guideline. Seoul : Elsevier Korea. 2016 : 84.
4 The Co-textbook Publishing Committee of Korean Oriental Medicine School. Herbal medicine. Seoul : Younglimsa. 2016 : 153.
5 Hwang MJ, Shin HD, Song MY. Review of literature on herbal medicines for the treatment of obesity in Korea: mainly papers since 2000. J Oriental Rehab Med. 2006 ; 16(3) : 65-81.
6 Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. Clinical Science. 1999 ; 96(5) : 483-91.   DOI
7 Jang IS, Yang CS, Hwang EH. The need for clinical practice guidelines in usage of Mahuang in weight loss. J Korean Med Obes Res. 2007 ; 7(1) : 23-9.
8 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011.
9 Persky AM, Berry NS, Pollack GM, Brouwer KL. Modelling the cardiovascular effects of ephedrine. Br J Clin Pharmacol. 2004 ; 57(5) : 552-62.   DOI
10 Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. International Journal of Obesity. 2001 ; 25(3) : 316-24.   DOI
11 Kim HJ, Han CH, Lee EJ, Song YK, Shin BC, Kim YK. A clinical practice guideline for Ma-huang (Ephedra sinica) prescription in obesity. J Korean Med Obes Res. 2007 ; 7(2) : 27-37.
12 Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol. 1978 ; 6(3) : 221-5.   DOI
13 Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. International Journal of Obesity. 2002 ; 26(5) : 593-604.   DOI
14 Hsing LC, Lee TH, Son DH, Yeo JJ, Yang CS, Seo ES, et al. Adverse effects of Ma-huang according to dose: a randomized double-blind placebo-controlled pilot study. Korean J Orient Int Med. 2006 ; 27(1) : 188-96.
15 Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. 2011 ; 99(1) : 1-9.   DOI
16 Greenway F L, D e Jonge L, B lanchard D , F risard M , Smith SR. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obesity Research. 2004 ; 12(7) : 1152-7.   DOI
17 Samenuk D, Link MS, Homoud MK, Contreras R, Theohardes TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002 ; 77(1) : 12-6.   DOI
18 Kim HJ, Park JM, Kim JA, Ko BP. Effect of herbal Ephedra sinica and Evodia rutaecarpa on body composition and resting metabolic rate: a randomized, double- blind clinical trial in Korean premenopausal women. J Acupunct Meridian Stud. 2008 ; 1(2) : 128-38.   DOI
19 Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017 ; 38(3) : 170-84.   DOI
20 Hackman RM, Havel PJ, Schwartz HJ, Rutledge JC, Watnik MR, Noceti EM, et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. International Journal of Obesity. 2006 ; 30(10) : 1545-56.   DOI
21 Coffey CS, Steiner D, Baker BA, Allison DB. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. International Journal of Obesity. 2004 ; 28(11) : 1411-9.   DOI